Pacific Therapeutics Combined IPF Treatment Awaiting US Patent Approval

Pacific Therapeutics Combined IPF Treatment Awaiting US Patent Approval

Clinical stage specialty pharmaceutical company Pacific Therpaeutics Ltd. has just obtained licensing for a drug technology that uses a rapid-acting oral disintegrating tablet (ODT), indicated for erectile dysfunction; and together with partner Montreal-based IntelGenx Corporation, a company focused on developing enhanced drug delivery systems, Pacific will be combining two already-approved…

Bristol-Myers and Calibr Sign Collaboration for Anti-Fibrotic Therapy

Biopharmaceutical Bristol-Myers Squibb Company and the non-profit organization California Institute for Biomedical Research (Calibr) have established a worldwide research collaboration focused on the development of novel small molecule anti-fibrotic therapies, as well as an exclusive license agreement for the company to develop, manufacture and commercialize preclinical compounds from Calibr that result from the…

CPF Names 2014 Most Important Year for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) recently published an overview of the most important 2014 developments regarding the research and treatment of pulmonary fibrosis (PF). The nonprofit organization, which was founded in 2001 with the purpose of accelerating research to find a cure for the disease, believes that…

Idiopathic Pulmonary Fibrosis: Patient Needs, Perceptions and Experiences

A new study provides improved understanding of the challenges faced by people with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers, which could help in the development of supportive care and could also improve quality of life in people afflicted with IPF. The study appeared December 23rd, 2014, in the…

Study Reveals Association Between Pulmonary Fibrosis and Rheumatoid Arthritis, Scleroderma Sine Scleroderma & ANCA Associated Vasculitis

A new study on Diffuse Parenchymal Lung Disease (DPLD) entitled “A case of pulmonary fibrosis associated with rheumatoid arthritis, scleroderma sine scleroderma and ANCA associated vasculitis” was published in SpringerPlus by Amritpal Singh Anand from Lakeland Rheumatology, St Joseph, USA, and colleagues. Diffuse parenchymal lung disease…

Diagnostic, Treatment Differences Between Idiopathic Pulmonary Fibrosis and Connective Tissue Disease Underscored

A new study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience” describes a prospective analysis performed in India to assess the burden of diffuse parenchymal lung diseases (DPLD), particularly two DPLD-causative disorders, idiopathic pulmonary…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums